Features of intravenous anti TB therapy in patients with first diagnosed pulmonary TB in the intensive phase of treatment
Loading...
Files
Date
Editor(s)
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Background. We determined the effectiveness of intravenous anti-TB drugs compared with their oral administration during the intensive phase of treatment.
Methods. 152 patients with newly diagnosed destructive pulmonary TB were randomized into 2 groups: Main (n=65) who received isoniazid (0.3 g), ethambutol (1.2 g) and sodium rifamycin (0.6 g) iv with pyrazinamide (2.0 g) per os and control (n=87) who received standard chemotherapy with the same drugs in the same doses orally.
Results. After intensive phase sputum conversion was found in all the patients main group and 71 (81.6±4.1 %) patients control p<0.05. Time of sputum conversion in main group was 1.6±0.1 months and 1.9±0.1 months in control, p>0.05. In patients with destructive TB time to sputum conversion was 1.7±0.1 months in main group and 2.2±0.2 months in control, p<0.05. Time of cavities healing in main group was 2.9±0.2 months and 3.9±0.2 months in the control, p<0.05.
Conclusions. Use of iv isoniazid, ethambutol and sodium rifamycin in the intensive phase of chemotherapy resulted in a significant reduction in terms of sputum conversion.
Description
Keywords
Citation
Features of intravenous anti TB therapy in patients with first diagnosed pulmonary TB in the intensive phase of treatment / M. Kuzhko, M. Gumeniuk, D. Butov, T. Tlustova, O. Denysov, T. Sprynsian // European Respiratory Society : International congress 2017, Milan, Italy, 9–13 September 2017. – Milan, 2017. – P. 4551.